Posts by
John Steuart
Sam Coates is a partner at Cooley, and a great friend and colleague of mine. He wrote this blog post just for us. Money, motorcycle racing and startups—it’s all about winning and losing Guest Post by Sam Coates “I like money,” one founder said to me bluntly, in response to my question about what […]
Read MoreSeptember 28, 2011 source: Wall Street Journal All good things, unfortunately, come to an end. The last year or two have been spectacular for entrepreneurs. Investor enthusiasm has been intense, meaning that start-ups had the upper hand and could get financing at extraordinarily generous terms. But I’m afraid that the curtain is about to fall. […]
Read MoreEntrepreneurs and venture-backed companies seeking financing in the near term, take notice. The hot market for companies is going to cool off in 3 to 6 months. Hurry up and get your round closed before it gets harder and terms get tougher. In my 20 years of participating in the venture market both as a […]
Read MoreClaremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If […]
Read MoreSuccessful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment. These challenges include the cost-efficient development of technology that is truly disruptive yet cost-competitive. Panelists will discuss how to best determine […]
Read MoreI will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center. Here’s the panel topic summary, hope to see you there. Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get […]
Read MoreMeet our team
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.
NAT GOLDHABER
Nat Goldhaber is a co-founder of Claremont Creek Ventures.
BRAD WEBB
Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.
RANDY HAWKS
Randy Hawks is a co-founder of Claremont Creek Ventures.